Quality assessment of platelet rich plasma during anti-platelet therapy.
Platelet rich plasma (PRP) is being used with increased frequency in many surgical procedures for its known benefits of accelerated surgical wound site healing. Speculations in its efficacy in the presence of anti-platelet therapy have been proposed. To aid in defining a quality platelet rich plasma product in the presence of acetylsalicylic acid (ASA) and Plavix (clopidogrel bisulfate), we investigated three (3) groups (n = 18) of cardiac surgical patients receiving PRP. Platelet function test, platelet concentration, and quantification of growth factors (PDGF-bb and TGF-b1) were evaluated. Results showed no statistical evidence of decreased growth factors delivered to the surgical wound site in the presence of acetylsalicylic acid (ASA) and/or Plavix (clopidogrel bisulfate). Evidence in this pilot study supports the use of PRP for patients receiving Plavix and aspirin therapy without compromising the quantity of specific growth factors delivered to a wound site.
Smith
Chad W
CW
Tennessee Perfusion Services, PLLC, Centennial Medical Center, Cardiothoracic Surgery, Nashville, Tennessee 37027, USA Chadsmail@comcast.net
Binford
Robert S
RS
Holt
David W
DW
Webb
David P
DP
D000368:Aged; D001241:Aspirin; D000077144:Clopidogrel; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010976:Platelet Count; D010979:Platelet Function Tests; D017713:Platelet Transfusion; D011785:Quality Assurance, Health Care; D013514:Surgical Procedures, Operative; D013988:Ticlopidine / Q000031:analogs & derivatives; D014945:Wound Healing
D036341:Intercellular Signaling Peptides and Proteins; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin